Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been assigned an average rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.33.
A number of research firms have issued reports on PIRS. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Pieris Pharmaceuticals in a research report on Friday, March 9th. Jefferies Financial Group began coverage on Pieris Pharmaceuticals in a research report on Monday, March 19th. They issued a “buy” rating and a $12.00 target price on the stock. BidaskClub cut Pieris Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 15th. Cowen began coverage on Pieris Pharmaceuticals in a research report on Friday, May 4th. They issued an “outperform” rating on the stock. Finally, ValuEngine upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.
In other news, insider Orbimed Advisors Llc sold 1,000,000 shares of Pieris Pharmaceuticals stock in a transaction dated Monday, April 30th. The stock was sold at an average price of $6.35, for a total transaction of $6,350,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James A. Geraghty purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $57,500.00. Following the completion of the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $115,000. The disclosure for this purchase can be found here. Insiders own 5.07% of the company’s stock.
Shares of NASDAQ PIRS traded down $0.02 during mid-day trading on Tuesday, reaching $5.19. The company had a trading volume of 2,057,814 shares, compared to its average volume of 572,769. Pieris Pharmaceuticals has a one year low of $4.41 and a one year high of $9.75. The stock has a market capitalization of $281.29 million, a P/E ratio of -12.98 and a beta of 1.65.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.14). Pieris Pharmaceuticals had a negative net margin of 65.40% and a negative return on equity of 96.56%. The business had revenue of $4.15 million during the quarter, compared to the consensus estimate of $11.39 million. research analysts anticipate that Pieris Pharmaceuticals will post -0.48 earnings per share for the current year.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.